News & Updates

Pentingnya vaksinasi dalam pencegahan dan pengendalian dengue terintegrasi di Asia Tenggara

Asia Tenggara merupakan salah satu wilayah dengan kasus infeksi dengue tertinggi, dengan Indonesia dan Thailand termasuk di antara negara-negara yang sangat endemis. Pada simposium yang disponsori oleh Takeda yang diadakan selama Konferensi 2nd APIC-ADVA Asia Pacific Summit on Infectious Diseases and Immunization di Singapura, para ahli berfokus pada vaksinasi sebagai komponen integral dari strategi pencegahan dan pengendalian dengue yang holistik di Asia Tenggara.  

*Artikel editorial di bawah ini didukung oleh Takeda Pharmaceuticals International AG Cabang Singapura dan hanya ditujukan untuk tujuan informasi. Takeda tidak memengaruhi atau berkontribusi pada konten editorial. Meskipun Takeda telah memberikan dukungan finansial untuk editorial ini, Takeda tidak bertanggung jawab atau berkewajiban atas kesalahan, kelalaian, atau ketidakakuratan dalam informasi tersebut.

Vaccination crucial to integrated dengue prevention and control in SEA

Southeast Asia (SEA) is one of the hotspots for dengue infections, with Indonesia and Thailand among the highly endemic countries. At a Takeda-sponsored symposium held during the 2nd APIC-ADVA Asia Pacific Summit on Infectious Diseases and Immunization in Singapore, experts focused on vaccination as an integral component of a holistic dengue prevention and control strategy in SEA.

*The editorial below is supported by Takeda Pharmaceuticals International AG Singapore Branch and is intended solely for informational purposes. Takeda has not influenced or contributed to the editorial content. While Takeda has provided financial support for the editorial, Takeda shall not be held responsible or liable for any errors, omissions, or inaccuracies in such information.

Role of CGRP in acute migraine treatment and prevention: Evolving strategies and regional insights

This article highlights key insights from the Asia Migraine Healers Academy 2025, a Pfizer-organized event in Kuala Lumpur, Malaysia, where renowned experts Professor Andrew Charles (US) and Dr Mianwang He (China) discussed advancements in migraine management.

What’s new, what’s hot in diabetes management: Snippets from ATTD-ASIA

ATTD-ASIA 2024, held recently in Singapore, was a huge success, with nearly 800 delegates from 49 countries gracing the event. ATTD-Asia 2024 chair, Professor Moshe Phillip, said the event brought together top diabetes experts to ensure patients can access the latest technologies and treatments for diabetes. MIMS Doctor reports highlights and snippets from the conference.

Podcasts@ATTD-ASIA: Experts share how CGM transforms diabetes care

Podcasts@ATTD-ASIA: Experts share how CGM transforms diabetes care

Navigating invasive candidiasis diagnosis and management in non-neutropenic ICU patients

At a recent Pfizer-sponsored webinar, Dr Paula Ramirez Galleymore, an Intensive Care Medicine specialist from La Fe University and Polytechnic Hospital in Valencia, Spain, addressed the pressing issue of invasive candidiasis in the ICU — often an overlooked but frequent intruder in critical care settings. Galleymore discussed key aspects, including the primary risk factors associated with invasive Candida infections, emphasizing the need for early intervention to improve patient outcomes. She also explored antifungal treatment options, focusing on the clinical efficacy and guideline recommendations for echinocandins.

Advancing management of invasive mould disease: Expert insights and practical case study

Invasive mould diseases (IMD), such as invasive aspergillosis or mucormycosis, present significant diagnostic and management challenges, particularly in high-risk patients. A recent Pfizer-sponsored symposium brought together leading experts to discuss current guideline recommendations, diagnostic strategies, and therapeutic approaches to IMD. Chaired by Dr Asok Kurup, Infectious Diseases Physician and Chair of the Infection Control Committee at Mount Elizabeth Hospital, Singapore, the session featured a presentation by Professor Deborah Marriott, Senior Specialist in Clinical Microbiology and Infectious Diseases, St. Vincent’s Hospital in Australia. The symposium provided practical, evidence-based strategies to improve outcomes for high-risk patients and advance IMD care.

Nirmatrelvir-ritonavir efficacy and risk factors for COVID-19 hospitalization

The post-pandemic burden of COVID-19 remains significant in adults. Four studies from IDWeek 2024 highlight the benefits of nirmatrelvir-ritonavir (NMV/r) for high-risk adults with SARS-CoV-2 immunity and link chronic conditions to COVID-19 hospitalization. Identifying high-risk patients and using NMV/r in outpatient settings can reduce severe outcomes.

Clinical considerations for patients at high risk for progression to severe COVID-19

COVID-19 has not gone away. New contagious variants continue to be a leading cause of death, with underlying conditions still influencing the risk of COVID-19 hospitalizations, said Dr Ali Hassoun, Clinical Professor of Medicine and infectious disease specialist at Crestwood Medical Center, Huntsville, Alabama, US, who spoke at a Pfizer-sponsored session during IDWeek 2024.

Ropeginterferon alfa-2b supports a shift in polycythaemia vera treatment

Professor Jean-Jacques Kiladjian, Professor of Clinical Pharmacology, Consultant Haematologist, and head of the Clinical Investigation Centre of Hôpital Saint-Louis & Université Paris Cité in Paris, France, discusses the drawbacks of conventional therapy for PV, and how ropeginterferon alfa-2b may support a shift in treatment.